- Home
- HHS vs RPHM Comparison
HHS vs RPHM Comparison
Compare HHS & RPHM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HHS
- RPHM
- Stock Information
- Founded
- HHS 1923
- RPHM 2014
- Country
- HHS United States
- RPHM United States
- Employees
- HHS N/A
- RPHM N/A
- Industry
- HHS Advertising
- RPHM Biotechnology: Pharmaceutical Preparations
- Sector
- HHS Consumer Discretionary
- RPHM Health Care
- Exchange
- HHS Nasdaq
- RPHM Nasdaq
- Market Cap
- HHS 55.0M
- RPHM 47.5M
- IPO Year
- HHS N/A
- RPHM 2021
- Fundamental
- Price
- HHS $7.25
- RPHM $18.20
- Analyst Decision
- HHS
- RPHM Hold
- Analyst Count
- HHS 0
- RPHM 6
- Target Price
- HHS N/A
- RPHM $2.26
- AVG Volume (30 Days)
- HHS 15.4K
- RPHM 345.4K
- Earning Date
- HHS 11-07-2024
- RPHM 11-11-2024
- Dividend Yield
- HHS N/A
- RPHM N/A
- EPS Growth
- HHS N/A
- RPHM N/A
- EPS
- HHS N/A
- RPHM N/A
- Revenue
- HHS $187,093,000.00
- RPHM N/A
- Revenue This Year
- HHS N/A
- RPHM N/A
- Revenue Next Year
- HHS $4.05
- RPHM N/A
- P/E Ratio
- HHS N/A
- RPHM N/A
- Revenue Growth
- HHS N/A
- RPHM N/A
- 52 Week Low
- HHS $5.39
- RPHM $1.68
- 52 Week High
- HHS $8.87
- RPHM $92.10
- Technical
- Relative Strength Index (RSI)
- HHS 44.49
- RPHM 69.89
- Support Level
- HHS $6.66
- RPHM $16.10
- Resistance Level
- HHS $7.41
- RPHM $17.50
- Average True Range (ATR)
- HHS 0.25
- RPHM 1.35
- MACD
- HHS -0.03
- RPHM 0.36
- Stochastic Oscillator
- HHS 55.66
- RPHM 87.30
About HHS Harte-Hanks Inc.
Harte-Hanks Inc is a customer experience company. The Company operates three business segments: Marketing Services; Customer Care; and Fulfillment & Logistics Services. The company has a geographic presence in the United States and Other countries. The majority of the revenue is earned from the United States.
About RPHM Reneo Pharmaceuticals Inc.
Reneo Pharmaceuticals Inc is a clinical-stage pharmaceutical company. It is focused on the development of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). The company is developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the primary source of energy for cellular processes.